The FDA is seeking to cut time to first-in-human studies through a new regulatory pathway described as optional and risk-based. The proposal is intended for experimental drugs with existing preclinical data that can be confirmed without animal testing, shifting the start of clinical development earlier in some cases. In the coverage, the FDA’s budget proposals were positioned as more ambitious than similar policies used in jurisdictions such as Australia, China, and the U.K., but implementation could take years depending on policy rollout. Congressional action would be required to create the new pathway. For biotech companies, especially smaller sponsors that operate on limited financing timelines, the change would primarily affect the bottleneck risk around first human dosing and associated administrative overhead.